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and specific angiotensin II antagonist acting on the AT1 
receptor subtype. Its empirical formula is C24H29N5O3, its 
molecular weight is 435.5. Valsartan is a white fine powder. 
It is soluble in ethanol and methanol and slightly soluble 
in water. It is available as tablets for oral administration, 
containing 40 mg, 80 mg, 160 mg, or 320 mg of valsartan.
According to current good manufacturing practices, all 
drugs must be tested with a stability-indicating assay method 
before release. Stress testing of the drug substance can help 
identify the likely degradation products, which can in turn 
help establish the degradation pathways and the intrinsic 
stability of the molecule and validate the stability-indicating 
power of the analytical procedures used. The nature of the 
stress testing will depend on the individual drug substance 
and the type of drug product involved. Keeping into the view 
of susceptibility of valsartan under variety of conditions, it 
was felt that a HPLC method of analysis that separates the 
INTRODUCTION
Valsartan is chemically described as N-(1-oxopentyl)-
N-[[2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-L-
valine [Figure 1]. Valsartan is a nonpeptide, orally active, 
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ABSTRACT
A stability-indicating HPLC assay method has been developed and validated for valsartan in bulk drug and 
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drug from the degradation products formed under ICH 
suggested conditions (hydrolysis, oxidation, photolysis, and 
thermal stress)[1] would be of general interest. These studies 
provide valuable information on drug’s inherent stability 
and help in the validation of analytical methods to be used 
in stability studies.[2] A survey on literature reveals that a 
very few methods were developed for the estimation of 
valsartan in biological fluids and marketed formulations.[3-10] 
The literature has demonstrated that a stability-indicating LC 
method for determination of valsartan in the presence of its 
impurities and degradation products generated from forced 
decomposition studies was developed.[11] Nevertheless, in 
that reported study, the retention time of valsartan was 
obtained at 27 min. However, in our present method the 
retention time of valsartan was achieved at 9.3 min. Thus, 
the aim of our study was to develop a simple, selective, 
economic, specific stability indicating the LC method that 
can be used to determine the related substances and also the 
assay of bulk samples of valsartan. This paper deals with 
the development of stability indicating the analytical method 
using the samples generated from forced degradation studies. 
EXPERIMENTAL DETAILS
Materials
Gift sample of valsartan was received from analytical 
research and development laboratory of International 
Speciality Product, Hyderabad, India. HPLC grade 
acetonitrile was purchased from Fischer Scientific, 
India. Analytical reagent grade sodium dihydrogen 
ortho-phosphate was purchased from S.D. Fine Chem. 
Limited, India, and hydrogen peroxide were purchased 
from Qualigens Fine Chemicals, India. High pure water 
was prepared by using Millipore Milli Q plus purification 
system. Valzar® commercial formulations were purchased 
from the local market. 
Instrumentation
The LC system, used for method development, forced 
degradation studies, and method validation was Waters 
2695 series (manufactured by Waters Technologies, USA) 
LC system with a diode array detector. The output signal 
was monitored and processed using Empower software 
(designed by Waters Technologies, USA) on lenovo 
computer (Digital Equipment Co.).
Chromatographic conditions
The chromatographic column used was Waters using 
Symmetry C18 (250mm × 4.6mm × 5µ). The mobile 
phase consists of a mixture of 0.02 mM sodium 
dihydrogen ortho-phosphate, pH adjusted to 2.5 using 
ortho-phosphoric acid (solvent A), and acetonitrile (solvent 
B) in 58: 42 ratio. The mobile phase was pumped from the 
solvent reservoir to the column at a flow rate of 1 ml/min 
for 20 min. The column temperature was maintained at 
23 ± 1 °C. The eluate was monitored at 250 nm using the 
PDA detector. The injection volume was 10 (μl). Mobile 
phase was used as diluent during the standard and test 
samples preparation.
Preparation of standard solutions
Stock solution of valsartan was prepared by dissolving 25 
mg of valsartan in 25 ml of volumetric flask containing 20 
ml acetonitrile. The solution was sonicated for about 20 min 
and then made up to volume with acetonitrile. Aliquots of 
the standard stock solution of valsartan were transferred 
using A-grade bulb pipettes into 10 ml volumetric flasks 
and the solutions were made up to volume with mobile 
phase to give final concentrations of 1,5,50,100,150, and 
200 µg/ml.
Preparation of valsartan tablets for assay
Twenty tablets were weighed, finely powdered, and an 
accurately weighed sample of powdered tablets equivalent 
to 25 mg of valsartan was treated with acetonitrile and 
phosphate buffer (pH 2.5) in a 25 ml volumetric flask using 
ultra sonicator. This solution was filtered through 0.45 
µm filter paper. Suitable aliquot of the filtered solution 
was added to a volumetric flask and made up to volume 
with mobile phase to yield a starting concentration of 0.1 
mg/ml. 
Forced degradation studies 
In order to determine whether the analytical method 
and assay were stability-indicating, valsartan tablets and 
valsartan active pharmaceutical ingredient (API) powder 
were stressed under various conditions to conduct 
forced degradation studies. Intentional degradation was 
attempted to stress conditions acid hydrolysis (using 
0.75N, 1.5N HCl), base hydrolysis (using 1.5N NaOH), 
oxidative degradation (using 3.0%, 10% H2O2), photolytic 
degradation (UV cabinet, an overall illumination of ≥210 
Wh/m2 at room temperature with UV radiation at 320–
400 nm), and thermal treatment (heated at 50°C, 80°C 
for 2 h) to evaluate the ability of the proposed method 
to separate valsartan from its degradation products. 
Valsartan at a concentration of 0.5 mg/ml was used 
in all the degradation studies. After completion of the 
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degradation processes, the solutions were neutralized and 
diluted with mobile phase.
Acid and alkaline degradation 
Forced degradation in acidic media was performed by 
taking an aliquot of stock solution in a 10 ml volumetric 
flask and diluted up to the mark with HCl (0.75 N, 1.5 
N) to obtain a final concentration of 100 mcg/ml. The 
flask was kept aside at room temperature for 2 h and 
neutralized. Appropriate aliquot was taken from the 
above solution and diluted with mobile phase to obtain 
a final concentration of 10 mcg/ml. Similarly, forced 
degradation in alkaline media was performed using 1.5 
N NaOH. The representative chromatograms for acid 
and alkaline degradation studies are shown in Figures 2 
and 3, respectively.
Oxidative degradation
Oxidative degradation was performed by taking an aliquot 
of stock solution in a 10 ml volumetric flask and diluted 
up to the mark with hydrogen peroxide (3.0%, 10%) to 
obtain a final concentration of 100 mcg/ml. The flask 
was kept aside at room temperature for 2 h. Appropriate 
aliquot was taken from the above solution and diluted with 
mobile phase to obtain a final concentration of 10 mcg/
ml. The representative chromatogram is shown in Figure 4.
Photo stability
Valsartan-API, tablet powder, and solutions of both were 
prepared and exposed to light to determine the effects of 
light irradiation on the stability of valsartan in solution and 
in the solid state. Approximately 50 mg of valsartan-API 
powder was spread on a glass dish in a layer that was less 
than 2 mm thickness and a solution of API (1 mg/ml) was 
prepared in mobile phase. Tablet powder was also prepared 
in the same way. All samples for photo-stability testing 
were placed in a light cabinet and exposed to light for 2 
h resulting in an overall illumination of ≥210 Wh/m2 at 
25 °C with UV radiation at 320-400 nm. Control samples, 
which were protected with aluminum foil, were also placed 
in the light cabinet and exposed concurrently. Following 
removal from the light cabinet, all samples were prepared 
for analysis as previously described. The representative 
chromatogram is shown in Figure 5. 
Thermal stress studies
For thermal stress, valsaratan-API, tablet powder, and 
solutions of both were prepared and exposed to a 
controlled temperature oven at 50oC and 80oC for 2 h. 
The representative chromatogram is shown in Figure 6. 
Stability indicating LC method for valsartan
Figure 2: Typical chromatogram representing the degradation behavior 
of valsartan in acid hydrolysis
Figure 3: Typical chromatogram representing the degradation behavior 
of valsartan in alkaline hydrolysis
Figure 4: Typical chromatogram representing the degradation behavior 
of valsartan in oxidative hydrolysis
Figure 5: Typical chromatogram representing the degradation behavior 
of valsartan in liquid state photo-stability186   J Young Pharm Vol 2 / No 2
Figure 6: Typical chromatogram representing the degradation behavior 
of valsartan in temperature stress studies
RESULTS AND DISCUSSION
HPLC method: Development and optimization
The chromatographic column used was Waters Symmetry 
C18 250 × 4.6 mm × 5 µm and it was maintained at ambient 
temperature for the separation and the method validated for 
the determination of valsartan tablets. The composition, 
pH, and the flow rate of the mobile phase were changed to 
optimize the separation conditions using stressed samples 
and the main related substances. A mobile phase consisting 
of 0.02 mM NaH2PO4 buffer (pH 2.5) and acetonitrile 
(58:42, %v/v) is selected at a flow rate of 1 ml/min, after 
several preliminary investigatory chromatographic runs. 
Under the described experimental conditions, all peaks 
were well defined and free from tailing. The effects of 
small deliberate changes in the mobile phase composition, 
pH, and flow rate were evaluated as a part of testing for 
method robustness. 
Results of forced degradation studies 
Forced degradation studies were performed for bulk drug 
and tablet powder, to provide an indication of the stability 
indicating property and specificity of the proposed method. 
Intentional degradation was attempted to under different 
stress conditions to evaluate the ability of the proposed 
method to separate valsartan from its degradation products. 
Degradation was not observed in valsartan samples under 
stress conditions like acid hydrolysis, alkaline hydrolysis, and 
thermal exposure. However, mild degradation was observed 
when the drug was exposed to photolysis (UV cabinet at 
320–400nm) and hydrogen peroxide. The concentration 
of valsartan was more slightly decreasing with time in 
hydrogen peroxide and UV light. This degradation is mainly 
observed in terms of loss of assay. Table 1 indicates the 
extent of degradation of valsartan under various stress 
conditions. Therefore, it may be concluded that valsartan 
is susceptible to degrade in oxidative and photolytic 
conditions. Photodiode array detection was used as an 
evidence of the specificity of the method and to evaluate 
the homogeneity of the drug peak. Chromatographic 
peak purity data were obtained from the spectral analysis 
report and a peak purity value greater than 990 indicates 
a homogenous peak. The peak purity values for analyte 
peaks in chromatograms of stressed samples were in the 
range of 999–1000 for drug substance, and in the range 
of 997–999 for tablets, indicating homogenous peaks 
and thus establishing the specificity of the assay method. 
Resolution between the analyte peaks and nearest peak 
was more than 2.0 in all the chromatograms. Figures 2 to 6 
show the chromatograms of forced degraded samples. The 
degradation products were well resolved from valsartan, 
confirming the stability-indicating power of the method.
Validation of the method
The analytical method was validated with respect to 
parameters such as linearity, limit of quantitation (LOQ), 
limit of detection (LOD), precision, accuracy, selectivity, 
recovery, and robustness/ruggedness.
Linearity
Linearity was established by least squares linear regression 
Table 1: Summary of forced degradation results
Stress condition Time (h) % Recovery Retention time of the analyte Peak purity
Acid hydrolysis (0.75 N HCl at RT 2 97.93 9.17 999
Acid hydrolysis (1.5 N HCl at RT) 2 96.46 9.24 999
Base hydrolysis (0.75N NaOH at RT) 2 97.13 9.16 999
Base hydrolysis (1.5N NaOH at RT) 2 97.13 9.16 999
Oxidation (3% H2O2 at RT) 2 96.33 9.16 999
Oxidation (10% H2O2 at RT) 2 37.40 9.26 999
Photolysis (UV cabinet at 320–400 nm) 2 94.41 9.27 999
Thermal treatment (50 oC) 2 101.71 9.15 999
Thermal treatment (80 oC) 2 101.42 9.28 999
RT-room temperature; API-Active Pharmaceutical Ingredient; cmean peak area is the average of three determinations
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analysis of the calibration curve. The constructed 
calibration curves were linear over the concentration 
range of 1–200 μg/ml. Peak areas of valsartan was 
plotted against their respective concentrations and linear 
regression analysis performed on the resultant curve. 
Correlation coefficient (n=3) was found to be more than 
0.999 with %RSD values being less than 2% across the 
concentration ranges studied. Typically, the regression 
equation was
y = 17905x + 1137 (R = 0.9999)
Limit of Detection and Limit of Quantitation 
The limit of quantitation (LOQ) of the present method 
was found to be 0.993 µg/ml with a resultant %RSD of 
0.4% (n = 5). The limit of detection (LOD) was found to 
be 0.3 µg/ml. The representative chromatograms for blank 
run and chromatogram at LOQ were shown in Figures 7 
and 8, respectively.
Precision
Precision of the assay was investigated with respect to 
both repeatability and reproducibility. Repeatability was 
investigated by injecting nine replicate samples of each 
of the 25, 50, and 75 µg/ml standards where the mean 
concentrations were found to be 25.5, 50.2, and 74.8 
µg/ml with associated %RSDs of 0.23, 1.24, and 0.42, 
respectively. Inter-day precision was assessed by injecting 
the same three concentrations over three consecutive 
days, resulting in mean concentrations of valsartan of 
24.0, 50.3, and 74.1 µg/ml and associated %RSDs of 
1.33, 1.59, and 1.7%, respectively. The ruggedness of the 
method was assessed by comparison of the intra- and 
inter-day assay results for valsartan undertaken by two 
analysts. The %RSD values for intra- and inter-day assays 
of valsartan in the cited formulations performed in the 
same laboratory by the two analysts did not exceed more 
than 2%, thus indicating the ruggedness of the method. 
The mean retention time of valsartan was 9.2 min with 
associated %RSD of 0.1%.
Accuracy
The accuracy of the method was determined through the 
recovery test of the samples, using known amounts of 
valsartan reference standard. For the LC method, aliquots 
of 0.8, 1.0, and 1.2 ml of a valsartan standard solution (50 
µg/ml) were added to three sample solutions containing a 
fixed amount of valsartan (50 µg) in diluent, respectively. 
Therefore, this recovery study was performed at a final 
concentration solution of 40.0, 50.0, and 60.0 µg/ml 
of valsartan. All solutions were prepared in triplicate 
and analyzed. Accuracy data for the assay following 
Figure 7: A representative chromatogram of the blank run Figure 8: A representative chromatogram of valsartan at LOQ
Figure 9: Typical chromatogram of valsartan in active pharmaceutical 
ingredient Figure 10: Typical chromatogram of valsartan in tablet dosage forms188   J Young Pharm Vol 2 / No 2
the determination of the compound of interest are 
summarized in Table 2.
Specificity
The specificity of the LC method was evaluated to 
ensure that there was no interference from the excipients 
contained in pharmaceutical product or from products 
resulting from forced degradation. The results of stress 
testing studies in addition to that of monitoring standard 
solutions of the drug in the presence of their impurities 
indicated a high degree of specificity of this method. 
The degradation product(s) of the parent compound was 
found to be similar for both the tablets and API powder. 
All the degradation products formed during forced 
decomposition studies were well separated from the 
analyte peak, demonstrating that the developed method 
was specific and stability-indicating. 
Robustness Test
As recommended in the ICH Guidelines, a robustness 
assessment was performed during the development of the 
analytical procedure. The robustness of the method was 
investigated under a variety of conditions including changes 
of pH of the eluent, flow rate, and buffer composition. The 
degree of reproducibility of the results obtained as a result 
of small deliberate variations in the method parameters 
and by changing analytical operators have proven that the 
method is robust and the data are summarized in Table 3.
System Suitability Parameters
System suitability parameters can be defined as tests to 
ensure that the method can generate results of acceptable 
accuracy and precision. The requirements for system 
suitability are usually developed after the completion 
of method development and validation. (Or) The USP 
(2000) defines parameters that can be used to determine 
system suitability prior to analysis. The system suitability 
parameters, such as Theoretical plates (N), Resolution 
(R), Tailing factor (T), were calculated and compared with 
the standard values to ascertain whether the proposed 
RP-HPLC method for the estimation of valsartan in 
pharmaceutical formulations was validated or not. The 
results are shown in Table 4.
Assay
The validated method was applied to the determination of 
valsartan in commercially available valzar tablets. Figures 
9 and 10 illustrate two typical HPLC chromatograms 
obtained following the assay of valsartan reference standard 
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solution and from valzar tablets, respectively. The results 
of the assay (n = 9) undertaken yielded 100.03% (%RSD 
= 1.40%) of label claim for valsartan. The observed 
concentration of valsartan was found to be 10.003±0.140 
µg/ml (mean±SD). The mean retention time of valsartan 
was 9.38 min. The results of the assay indicate that the 
method is selective for the analysis of valsartan without 
interference from the excipients used to formulate and 
produce these tablets.
Solution stability
The R.S.D. of assay of valsartan during solution stability 
experiments was within 1.0%. No significant change was 
observed in the content of valsartan during solution 
stability experiments. The experimental data confirmed that 
sample solutions used during assay and related substance 
determinations were stable up to 48 h.
CONCLUSIONS
A simple, rapid, accurate, and precise stability-indicating 
HPLC analytical method has been developed and validated 
for the routine analysis of valsartan in API and tablet 
dosage forms. The results of stress testing reveal that the 
method is selective and stability-indicating. The proposed 
method has the ability to separate the drug from their 
Table 4: System suitability parameters
Parameter Values obtained Preferable values
Theoretical plates (N) 7848 >2500
Resolution (R) 4.8 >1.5
Tailing factor 1.07 <1.5
Table 2: Accuracy data (n=3)
Amount of drug 
added (mg)
Mean amount of drug 
recovered (mg)
% drug 
recovery
% 
RSD
40 40.56±0.36 101.40 0.88
50 49.87±0.71 99.74 1.42
60 59.49±0.68 99.15 1.14
Data obtained from three replicates at each concentration.
Table 3: Robustness testing of the method
Parameter Modification % Drug recovery
pH 2.4 100.1
2 2.5 100.3
3 2.6 99.8
Buffer composition (mM) 0.01 98.5
0.02 101.2
0.03 100.8
Flow rate (ml/min) 0.9 100.5
1.0 100.1
1.1 101.3
Data obtained from three replicates at each concentration.J Young Pharm Vol 2 / No 2  189
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degradation products, related substances, and excipients 
found in tablet dosage forms and can be applied to the 
analysis of samples obtained during accelerated stability 
experiments.
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